SCHEMBL349467

SCHEMBL349467

COc1ccc(C(=O)Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.70
KMT2A Q03164 6/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
MEN1 O00255 2/20 0.64
CYP1A2 P05177 2/20 0.64
CYP2C9 P11712 2/20 0.64
CYP2C19 P33261 2/20 0.64
LMNA P02545 1/20 0.64
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
MAPT P10636 2/20 0.61
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
GFER P55789 1/20 0.59
PRSS1 P07477 1/20 0.59
ACR P10323 1/20 0.59
CYP11B1 P15538 1/20 0.59
CYP11B2 P19099 1/20 0.59
ALDH1A1 P00352 1/20 0.57
CYP3A4 P08684 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL532765 1.00 HPGD (0.70) HPGDKMT2ASMN1; SMN2MEN1CYP1A2
SCHEMBL7591660 0.90 LMNA (0.75) KMT2ASMN1; SMN2MEN1CYP1A2CYP2C9
SCHEMBL12608584 0.90 LMNA (0.75) KMT2ASMN1; SMN2MEN1CYP1A2CYP2C9
SCHEMBL28003430 0.90 KMT2A (0.69) HPGDKMT2ASMN1; SMN2MEN1CYP1A2
SCHEMBL610755 0.90 KMT2A (0.69) HPGDKMT2ASMN1; SMN2MEN1CYP1A2
SCHEMBL12633724 0.90 LMNA (0.75) KMT2ASMN1; SMN2MEN1CYP1A2CYP2C9
SCHEMBL9683516 0.90 KMT2A (0.69) HPGDKMT2ASMN1; SMN2MEN1CYP1A2
SCHEMBL9666088 0.90 LMNA (0.75) KMT2ASMN1; SMN2MEN1CYP1A2CYP2C9
SCHEMBL10599787 0.90 KMT2A (0.69) HPGDKMT2ASMN1; SMN2MEN1CYP1A2
SCHEMBL14393071 0.89 KMT2A (0.69) HPGDKMT2ASMN1; SMN2MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11117996-B2 Self-assembly composition for pattern formation and pattern forming method Oji Holdings Corporation (JP) 2021-09-14 US disclosed
US-20190211130-A1 SELF-ASSEMBLY COMPOSITION FOR PATTERN FORMATION AND PATTERN FORMING METHOD Oji Holdings Corporation (JP) 2019-07-11 US disclosed
EP-1719768-B1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORP (JP) 2012-04-25 EP disclosed
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-7973030-B2 Benzothiazepine and benzothiepine compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-07-05 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed
EP-1719768-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS Asahi Kasei Pharma Corporation (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117996-B2 Self-assembly composition for pattern formation and pattern forming method IAPP, SAMM50, MAN1B1 HPGD 4198/4885KMT2A 3948/4885SMN1; SMN2 1010/4885
US-20190211130-A1 SELF-ASSEMBLY COMPOSITION FOR PATTERN FORMATION AND PATTERN FORMING METHOD IAPP, SAMM50, MAN1B1 HPGD 4198/4885KMT2A 3948/4885SMN1; SMN2 1010/4885
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS SLC10A1, SREBF1, SPTLC1 HPGD 3931/4885KMT2A 404/4885SMN1; SMN2 4162/4885
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds SLC10A1, GOT1, CES1 HPGD 3807/4885KMT2A 486/4885SMN1; SMN2 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.